TABLE 1.

Patient Selection

Inclusion and Exclusion Criteria	Sample Size
Patients with multiple sclerosisa and with at least 1 claim for fingolimod, dimethyl fumarate, or teriflunomide from April 1, 2013, to June 30, 2013	6,243
	Fingolimod	Dimethyl Fumarate	Teriflunomide
Patients at index treatmentb	2,968	2,602	673
Aged 18 years or older at index datec	2,968	2,600	673
Patients continuously enrolled in medical and pharmacy benefits from index date to 12-month follow-up	2,380	1,931	505
Patients continuously enrolled in medical and pharmacy benefits in 365 days before index date	1,914	1,514	401
Excluded patients with ≥20 claims for 1 NDC number in 12-month follow-up period	1,913	1,510	399
Excluded patients with any claims for index treatment in 12 months before index date	196	1,510	144
Excluded patients in multiple cohorts	195	1,509	143
For dimethyl fumarate cohort only: excluded patients with only 1-day starter pack in the entire study period		1,508
For dimethyl fumarate cohort only: included patients who initiated dimethyl fumarate starter pack only		1,160

^aAt least 1 claim with an ICD-9-CM diagnosis code of multiple sclerosis (340).

^bThe date of first medication claim is the index date.

^cThe index drug was defined as the first newly initiated oral DMT (new starts) within the identification period.

DMT = disease-modifying therapy; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; NDC=National Drug Code.